At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 145 enrolled
Drug / intervention
Loncastuximab tesirinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
In Brief
A Phase 2 clinical trial evaluating Loncastuximab tesirine for Diffuse Large B-Cell Lymphoma Refractory and Diffuse Large B-cell Lymphoma Recurrent. Completed, enrolled 145 participants across 37 sites in 4 countries.
Detailed Summary
The purpose of this Phase 2 study is to evaluate the clinical efficacy and safety of Loncastuximab Tesirine (ADCT-402) in patients with relapsed or refractory Diffuse Large B-Cell Lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartAug 2018
Primary CompletionMay 2020
Study CompletionAug 2022
TodayJul 2026
First PostedJul 18, 2018
Enrollment StartAug 1, 2018
Primary CompletionMay 24, 2020
Study CompletionAug 9, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8.0 years ago
Interventions
Loncastuximab tesirinedrug
intravenous infusion